Jefferies Survey Suggests Positive Expectations for BioMarin (BMRN) Ahead of Data on 11/24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Buy PTC Therapeutics (PTCT) into the Kyndrisa Advisory Panel Tues - Oppenheimer
November 23, 2015 9:08 AM ESTOppenheimer analyst, Christopher Marai, anticipates a narrowly positive BioMarin (NASDAQ: BMRN) Kyndrisa panel outcome, and discussion highlighting key differentiation of PTC Therapeutics (NASDAQ: PTCT) data set, which would reflect positively on the Translarna package.
Key differences set Transarna's package above Kyndrisa... More
Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company
November 20, 2015 11:19 AM ESTNeedham & Company analyst Chad Messer said FDA concerns on BioMarin's drisapersen should be a positive for Sarepta Therapeutic (NASDAQ: SRPT) Eteplirse. The firm reiterated a Buy rating and price target of $55.
Messer commented, "The FDA released briefing documents for BioMarin's drisapersen this... More
BioMarin Pharma (BMRN) FDA briefing docs released
November 20, 2015 7:59 AM ESTBioMarin Pharma (NASDAQ: BMRN) FDA briefing docs released. LINK
Related stocks:
Sarepta Therapeutics (NASDAQ: SRPT)
Buy Sarepta (SRPT) Into Kyndrisa Briefing Documents and Panel Outcome - Oppenheimer
November 19, 2015 3:28 PM ESTOppenheimer analyst Christopher Marai said they would be buyers of Sarepta Therapeutic (NASDAQ: SRPT) into Kyndrisa briefing documents and panel outcome. The firm reiterated an Outperform rating and price target of $45.
"Tomorrow morning, the FDA will make available briefing documents (here) pertaining to the... More
Baird Expects FDA Rejection for Drisapersen and Eteplirsen (BMRN) (SRPT)
November 19, 2015 8:18 AM ESTBaird analyst, Brian Skorney, increasing belief is that the FDA is more likely to reject the NDA's for drisapersen and eteplirsen. He thinks the risk-reward is mildly skewed to the upside for BioMarin Pharma (NASDAQ: BMRN) (20% up/10% down) and massively so for Sarepta Therapeutics (NASDAQ: SRPT) (250%... More
Goldman Sachs Assumes BioMarin Pharmaceutical Inc. (BMRN) at Buy
November 18, 2015 8:33 AM ESTGoldman Sachs assumed coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Buy rating and a price target of $158. Analyst Salveen Richter sees risk/reward as favorable, with significant news flow in 2016.
"Our rating is driven by 1) significant upside via numerous catalysts... More
Oppenheimer Starts BioMarin Pharmaceutical Inc. (BMRN) at Perform
November 17, 2015 4:58 PM ESTOppenheimer initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Perform rating and a price target of $119.00.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $104.54 yesterday.
... More